| PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression H Tang, Y Liang, RA Anders, JM Taube, X Qiu, A Mulgaonkar, X Liu, ... The Journal of clinical investigation 128 (2), 580-588, 2018 | 482 | 2018 |
| Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade H Tang, Y Wang, LK Chlewicki, Y Zhang, J Guo, W Liang, J Wang, ... Cancer cell 29 (3), 285-296, 2016 | 453 | 2016 |
| Low-dose X-ray radiotherapy–radiodynamic therapy via nanoscale metal–organic frameworks enhances checkpoint blockade immunotherapy K Lu, C He, N Guo, C Chan, K Ni, G Lan, H Tang, C Pelizzari, YX Fu, ... Nature biomedical engineering 2 (8), 600-610, 2018 | 444 | 2018 |
| PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade Q Peng, X Qiu, Z Zhang, S Zhang, Y Zhang, Y Liang, J Guo, H Peng, ... Nature communications 11 (1), 4835, 2020 | 338 | 2020 |
| Immunotherapy and tumor microenvironment H Tang, J Qiao, YX Fu Cancer letters 370 (1), 85-90, 2016 | 299 | 2016 |
| LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration M Deng, X Gui, J Kim, L Xie, W Chen, Z Li, L He, Y Chen, H Chen, W Luo, ... Nature 562 (7728), 605-609, 2018 | 201 | 2018 |
| Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance Y Liang, H Tang, J Guo, X Qiu, Z Yang, Z Ren, Z Sun, Y Bian, L Xu, H Xu, ... Nature communications 9 (1), 4586, 2018 | 78 | 2018 |
| Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy H Tang, M Zhu, J Qiao, YX Fu Cellular & molecular immunology 14 (10), 809-818, 2017 | 76 | 2017 |
| BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer In Vivo C Li, Z Yang, Y Du, H Tang, J Chen, D Hu, Z Fan Clinical cancer research 20 (15), 4001-4013, 2014 | 60 | 2014 |
| Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2 S Sun, Y Cai, TZ Song, Y Pu, L Cheng, H Xu, J Sun, C Meng, Y Lin, ... Cell Research 31 (9), 1011-1023, 2021 | 54 | 2021 |
| Granzyme H of cytotoxic lymphocytes is required for clearance of the hepatitis B virus through cleavage of the hepatitis B virus X protein H Tang, C Li, L Wang, H Zhang, Z Fan The Journal of Immunology 188 (2), 824-831, 2012 | 43 | 2012 |
| Differential regulation of breast cancer bone metastasis by PARP1 and PARP2 H Zuo, D Yang, Q Yang, H Tang, YX Fu, Y Wan Nature communications 11 (1), 1578, 2020 | 33 | 2020 |
| RTA promoter demethylation and histone acetylation regulation of murine gammaherpesvirus 68 reactivation Z Yang, H Tang, H Huang, H Deng PloS one 4 (2), e4556, 2009 | 22 | 2009 |
| DNA sensing and immune responses in cancer therapy J Qiao, H Tang, YX Fu Current opinion in immunology 45, 16-20, 2017 | 17 | 2017 |
| Melanoma and immunotherapy bridge 2015: Naples, Italy. 1–5 December 2015 VGY Nanda, W Peng, P Hwu, MA Davies, G Ciliberto, L Fattore, ... Journal of Translational Medicine 14, 1-27, 2016 | 15 | 2016 |
| Type 3 innate lymphoid cell-derived lymphotoxin prevents microbiota-dependent inflammation Y Zhang, TJ Kim, JA Wroblewska, V Tesic, V Upadhyay, ... Cellular & Molecular Immunology 15 (7), 697-709, 2018 | 14 | 2018 |
| Immune evasion in tumor’s own sweet way H Tang, YX Fu Cell Metabolism 27 (5), 945-946, 2018 | 14 | 2018 |
| Deficiency of CD40 reveals an important role for LIGHT in anti-leishmania immunity I Okwor, G Xu, H Tang, Y Liang, YX Fu, JE Uzonna The Journal of Immunology 195 (1), 194-202, 2015 | 11 | 2015 |
| Targeting tertiary lymphoid structures for tumor immunotherapy H Tang, X Qiu, C Timmerman, YX Fu Tertiary Lymphoid Structures: Methods and Protocols, 275-286, 2018 | 10 | 2018 |
| Cutting edge: lymphotoxin signaling is essential for clearance of Salmonella from the gut lumen and generation of anti-Salmonella protective immunity JA Wroblewska, Y Zhang, H Tang, X Guo, C Nagler, YX Fu The Journal of Immunology 198 (1), 55-60, 2017 | 7 | 2017 |
